Abstract
High throughput screening (HTS) facilitates screening large numbers of compounds against a biochemical target of interest using validated biological or biophysical assays. In recent years, a significant number of drugs in clinical trails originated from HTS campaigns, validating HTS as a bona fide mechanism for hit finding. In the current drug discovery landscape, the pharmaceutical industry is embracing open innovation strategies with academia to maximize their research capabilities and to feed their drug discovery pipeline. The goals of academic research have therefore expanded from target identification and validation to probe discovery, chemical genomics, and compound library screening. This trend is reflected in the emergence of HTS centers in the public domain over the past decade, ranging in size from modestly equipped academic screening centers to well endowed Molecular Libraries Probe Centers Network (MLPCN) centers funded by the NIH Roadmap initiative. These centers facilitate a comprehensive approach to probe discovery in academia and utilize both classical and cutting-edge assay technologies for executing primary and secondary screening campaigns. The various facets of academic HTS centers as well as their implications on technology transfer and drug discovery are discussed, and a roadmap for successful drug discovery in the public domain is presented. New lead discovery against therapeutic targets, especially those involving the rare and neglected diseases, is indeed a Mount Everestonian size task, and requires diligent implementation of pharmaceutical industrys best practices for a successful outcome.
Keywords: High throughput screening, open innovation, drug discovery, academia, NIH Roadmap, EU-OpenScreen, target identification, probe discovery, intellectual property, new chemical entities, screening and data production, data analysis and dissemination, technology develop-ment, Molecular Libraries Pro-gram (MLP), Molecular Libraries Screening Centers Net-work (MLSCN), Molecular Libraries Probe Production Centers Network (MLPCN), ultra high throughput screening, high content screening, high-throughput microscopy, high con-tent analysis, Surface plasmon resonance, Enzyme-linked immunosorbent assays, fluorescence polarization, AlphaScreen, AlphaLI-SA, lactate dehydrogenase, heterogeneous cell viability assessment, heterogeneous absorbance-based LDH as-say, homogenous absorbance-based LDH assay, luminescence cyto-toxicity assay, Pipeline Pilot scientific data workflow platform, Activity base XE enable custom data processing, COX-2 inhibitor
Current Pharmaceutical Biotechnology
Title: Open Access High Throughput Drug Discovery in the Public Domain: A Mount Everest in the Making
Volume: 11 Issue: 7
Author(s): Anuradha Roy, Peter R. McDonald, Sitta Sittampalam and Rathnam Chaguturu
Affiliation:
Keywords: High throughput screening, open innovation, drug discovery, academia, NIH Roadmap, EU-OpenScreen, target identification, probe discovery, intellectual property, new chemical entities, screening and data production, data analysis and dissemination, technology develop-ment, Molecular Libraries Pro-gram (MLP), Molecular Libraries Screening Centers Net-work (MLSCN), Molecular Libraries Probe Production Centers Network (MLPCN), ultra high throughput screening, high content screening, high-throughput microscopy, high con-tent analysis, Surface plasmon resonance, Enzyme-linked immunosorbent assays, fluorescence polarization, AlphaScreen, AlphaLI-SA, lactate dehydrogenase, heterogeneous cell viability assessment, heterogeneous absorbance-based LDH as-say, homogenous absorbance-based LDH assay, luminescence cyto-toxicity assay, Pipeline Pilot scientific data workflow platform, Activity base XE enable custom data processing, COX-2 inhibitor
Abstract: High throughput screening (HTS) facilitates screening large numbers of compounds against a biochemical target of interest using validated biological or biophysical assays. In recent years, a significant number of drugs in clinical trails originated from HTS campaigns, validating HTS as a bona fide mechanism for hit finding. In the current drug discovery landscape, the pharmaceutical industry is embracing open innovation strategies with academia to maximize their research capabilities and to feed their drug discovery pipeline. The goals of academic research have therefore expanded from target identification and validation to probe discovery, chemical genomics, and compound library screening. This trend is reflected in the emergence of HTS centers in the public domain over the past decade, ranging in size from modestly equipped academic screening centers to well endowed Molecular Libraries Probe Centers Network (MLPCN) centers funded by the NIH Roadmap initiative. These centers facilitate a comprehensive approach to probe discovery in academia and utilize both classical and cutting-edge assay technologies for executing primary and secondary screening campaigns. The various facets of academic HTS centers as well as their implications on technology transfer and drug discovery are discussed, and a roadmap for successful drug discovery in the public domain is presented. New lead discovery against therapeutic targets, especially those involving the rare and neglected diseases, is indeed a Mount Everestonian size task, and requires diligent implementation of pharmaceutical industrys best practices for a successful outcome.
Export Options
About this article
Cite this article as:
Roy Anuradha, R. McDonald Peter, Sittampalam Sitta and Chaguturu Rathnam, Open Access High Throughput Drug Discovery in the Public Domain: A Mount Everest in the Making, Current Pharmaceutical Biotechnology 2010; 11 (7) . https://dx.doi.org/10.2174/138920110792927757
DOI https://dx.doi.org/10.2174/138920110792927757 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews Features for Heartbeat Sound Signal Normal and Pathological
Recent Patents on Computer Science The Role of Endothelin-1 in Obstructive Sleep Apnea Syndrome and Pulmonary Arterial Hypertension: Pathogenesis and Endothelin-1 Antagonists
Current Medicinal Chemistry Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Neuroprotective Mechanisms of Oxygen and Ethanol: A Potential Combination Therapy in Stroke
Current Medicinal Chemistry Actions of Selected Cardiovascular Hormones on Arterial Stiffness and Wave Reflections
Current Pharmaceutical Design Targeting Strategies in Therapeutic Applications of Toxoplasmosis: Recent Advances in Liposomal Vaccine Delivery Systems
Current Drug Targets Association of Lower Adiponectin Plasma Levels, Increased Age and Smoking with Subclinical Atherosclerosis in Patients with HIV-1 Infection
Current HIV Research Acute Myocardial Infarction in Systemic Mastocytosis: Case Report With Literature Review on the Role of Inflammatory Process in Acute Coronary Syndrome
Current Cardiology Reviews The Effects of Smoking Cessation on Diabetes Mellitus Patients
Current Diabetes Reviews Towards an Experimental and Systems Biology Framework for Cancer Cell Therapeutics
Current Bioinformatics Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis
Current Neurovascular Research Herbal Medicines for Diabetes Management and its Secondary Complications
Current Diabetes Reviews Imidazole Scaffold Based Compounds in the Development of Therapeutic Drugs
Current Topics in Medicinal Chemistry Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety Nutrient and Qualitative Phytochemical Analysis-evaluation of Antimicrobial Activity and Development of Products with Mulberry Leaves (<i>Mulberry indica</i> L.)
Current Nutrition & Food Science Blood Pressure and White Matter Lesions in Patients with Vascular Disease: The SMART-MR Study
Current Neurovascular Research 3, 5-Diiodothyronine: Biological Actions and Therapeutic Perspectives
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Hemodynamic Monitoring in the Acute Management of Pediatric Heart Failure
Current Cardiology Reviews Novel Risk Factors Related to Stable Angina
Current Pharmaceutical Design